Video: Treating Androgen
Independent Prostate Cancer Without Chemotherapy
Scholz, MD - Prostate Oncology Specialists
In this presentation, Dr. Scholz discussed the parameters for determining
hormone refractory prostate cancer such as a rising PSA or one that
fails to drop below 0.05 using Testosterone
He reviewed the pros and cons of available secondary hormonal manipulations
including: anti-androgens, ketoconazole and estrogens. He emphasized
these should normally be used only for men with slow-growing cancer.
He also discussed the use of drugs that enhance the immune system and/or
provide anti-angiogenic activity like Thalidomide, Revlimid and Leukine.
Androgen deprivation therapy (ADT also called hormone blockade or
testosterone inactivating pharmaceuticals) is a primary treatment
of prostate cancer that is outside the prostate at diagnosis or recurrent
after local therapy. When ADT fails to fully control the cancer,
type and timing of further treatment depends on the aggressiveness
of the cancer and the patientâ€™s ability to tolerate anticipated
side-effects. While chemotherapy may be suggested, milder treatments
discussed here can often provide effective cancer control with
This presentation was one of several given at the Prostate
Cancer Research Instituteâ€™s September, 2006 conference “Improving
Treatment and Quality of Life For Men with Recurrent and Advanced Prostate
Cancer” held in Los Angeles, CA, USA. The Prostate Cancer Research
Institute (PCRI) is a 501(c)(3) charitable organization whose mission
is to improve the quality of menâ€™s lives by supporting research
and disseminating information that educates and empowers patients,
families and the medical community.
Much more information is available in our PCRI
Papers page and elsewhere on this Web site.
More videos are listed in our Online